Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides
Author:
Open Access
- 15 January 1992
- journal article
- Published by American Society of Hematology in Blood
- Vol. 79 (2) , 430-438
Abstract
Lipoprotein-associated coagulation inhibitor (LACI) is a plasma-derived protein that inhibits tissue factor (TF)/factor VIIa-induced coagulation in a factor Xa-dependent manner. The roles of endogenous plasma LACI and exogenously added LACI and heparin, in the regulation of coagulation, initiated via the intrinsic and extrinsic pathways, were studied using the activated partial thromboplastin time (APTT) and the modified prothrombin time (PT) assays, respectively. Both LACI- depleted plasma and normal plasma have identical APTTs and similar prolongations of the APTT in response to heparin; both are fully anticoagulated (arbitrarily defined as clotting times of greater than 1 hour) at similar concentrations of heparin. These results indicate that heparin is an effective anticoagulant when coagulation is initiated by the intrinsic pathway and that endogenous LACI is not significantly involved in the regulation of this pathway. The PT of normal plasma is only marginally longer than that of LACI-depleted plasma in the absence of heparin, suggesting that endogenous plasma LACI has a very limited capacity to inhibit TF-induced clotting. However, in the presence of heparin, the PTs of LACI-depleted plasma and normal plasma are different. Prolongation of the PT occurred only moderately and linearly with increasing concentrations of heparin in LACI-depleted plasma. In contrast, normal plasma showed a greater extent of PT prolongation in response to heparin and the plasma became fully anticoagulated at a certain threshold concentration of heparin. These results suggest that LACI serves as a cofactor for heparin and thus greatly enhances the inhibition of TF-induced coagulation. LACI-depleted plasma was supplemented with purified recombinant LACI and/or heparin and the effects on TF-induced clotting were studied. A combination of LACI and heparin greatly enhanced anticoagulation compared with LACI or heparin alone. Many sulfated polysaccharides were also found to enhance the LACI-dependent inhibition of TF-induced clotting. By weight, the relative potencies of these compounds are: low molecular weight heparin (mean Mr, 5,100) greater than unfractionated heparin greater than low molecular weight heparin (mean Mr, 3,700) greater than pentosan polysulfate greater than dermatan sulfate greater than dextran sulfate greater than heparan sulfate. Based on the above results, it is concluded that LACI is a cofactor for heparin in the inhibition of TF- induced clotting and that LACI and sulfated polysaccharides act synergistically in whole plasma.Keywords
This publication has 14 references indexed in Scilit:
- Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells. A comparative study.Journal of Biological Chemistry, 1990
- Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)Thrombosis Research, 1988
- Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.Journal of Biological Chemistry, 1988
- Regulation of factor viia activity in plasma: evidence that antithrombin iii is the sole plasma protease inhibitor of human factor viiaThrombosis Research, 1987
- Thrombin generation and inactivation in the presence of antithrombin III and heparinBiochemistry, 1986
- Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan.Journal of Biological Chemistry, 1986
- [33] Immobilized anhydrotrypsin as a specific affinity adsorbent for tryptic peptides1983
- Anti-clotting activity of endothelial cell cultures and heparan sulfate proteoglycansBiochemical and Biophysical Research Communications, 1982
- The inhibition of activated bovine coagulation factors X and VII by antithrombin IIIArchives of Biochemistry and Biophysics, 1978
- The observation of heparin on endothelium after injectionThrombosis Research, 1976